Oprelvekin

Drug Profile

Oprelvekin

Alternative Names: Interleukin-11; Neumega; Recombinant human-interleukin-11; rhIL-11; SCH-53620; YM-294

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Class Antineoplastics; Chemoprotectants; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 11 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Bacteraemia; Crohn's disease; Graft-versus-host disease; Inflammatory bowel diseases; Mucositis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 04 Nov 2004 Discontinued - Preregistration for Thrombocytopenia in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top